Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Buono

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|September 26, 2022
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approachAlessandra Fabi, Giuseppe Buono, Emilio Bria, et al.
Molecular and Clinical Oncology|April 8, 2020
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report seriesFrancesco Schettini, Irene De Santo, Carmen G Rea, et al.
Clinical Breast Cancer|November 19, 2019
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational StudyBenedetta Conte, Alessandra Fabi, Francesca Poggio, et al.
Oncotarget|February 1, 2018
Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational studyGiuseppe Buono, Anna Crispo, Mario Giuliano, et al.
Breast (Edinburgh, Scotland)|December 30, 2017
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Mario Giuliano, Francesco Schettini, et al.
Breast (Edinburgh, Scotland)|June 27, 2026
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trialChiara Molinelli, Virginia Delucchi, Eva Blondeaux, et al.
La Radiologia Medica|February 8, 2023
Efficacy of recanalization therapy for ischemic stroke: multicenter hospital network experienceFrancesco Briganti, Mario Tortora, Fabio Tortora, et al.
Oncology|December 7, 2021
Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?Alessandra Fabi, Mariangela Ciccarese, Sinome Scagnoli, et al.
Cancer Treatment Reviews|December 22, 2024
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysisFrancesco Schettini, Sabrina Nucera, Tomás Pascual, et al.
Breast Cancer Research and Treatment|June 6, 2020
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational studyGiuseppe Buono, Anna Crispo, Mario Giuliano, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|September 26, 2022
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approachAlessandra Fabi, Giuseppe Buono, Emilio Bria, et al.
Molecular and Clinical Oncology|April 8, 2020
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report seriesFrancesco Schettini, Irene De Santo, Carmen G Rea, et al.
Clinical Breast Cancer|November 19, 2019
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational StudyBenedetta Conte, Alessandra Fabi, Francesca Poggio, et al.
Oncotarget|February 1, 2018
Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational studyGiuseppe Buono, Anna Crispo, Mario Giuliano, et al.
Breast (Edinburgh, Scotland)|December 30, 2017
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Mario Giuliano, Francesco Schettini, et al.
Breast (Edinburgh, Scotland)|June 27, 2026
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trialChiara Molinelli, Virginia Delucchi, Eva Blondeaux, et al.
La Radiologia Medica|February 8, 2023
Efficacy of recanalization therapy for ischemic stroke: multicenter hospital network experienceFrancesco Briganti, Mario Tortora, Fabio Tortora, et al.
Oncology|December 7, 2021
Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?Alessandra Fabi, Mariangela Ciccarese, Sinome Scagnoli, et al.
Cancer Treatment Reviews|December 22, 2024
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysisFrancesco Schettini, Sabrina Nucera, Tomás Pascual, et al.
Breast Cancer Research and Treatment|June 6, 2020
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational studyGiuseppe Buono, Anna Crispo, Mario Giuliano, et al.
Pageof 5